LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025

Reuters

2025/11/18

LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025

LifeMD Inc. reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584671041"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584671041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584671041?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584671041","market":"fut","top_or_hot":-1,"title":"LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LFMD\">LifeMD Inc.</a> reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LFMDP\">LifeMD Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-18 05:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LFMD\">LifeMD Inc.</a> reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LFMDP\">LifeMD Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"個人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbbkmtS:1","article_id":"2584671041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584671041","pubTimestamp":1763413898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LifeMD Inc. reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BK4167":"医疗保健技术","LFMD":"LifeMD Inc."},"translate_title":"LifeMD报告2025年第三季度收入增长13%，调整后EBITDA增长20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":0.9},"content_text":"LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n    \n\nLifeMD Inc. reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}